Related references
Note: Only part of the references are listed.Comparative In Vitro and In Vivo Efficacies of Human Simulated Doses of Ceftazidime and Ceftazidime-Avibactam against Pseudomonas aeruginosa
Jared L. Crandon et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
In Vitro Antibacterial Activity of the Ceftazidime-Avibactam (NXL104) Combination against Pseudomonas aeruginosa Clinical Isolates
Premavathy Levasseur et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
NXL104 Irreversibly Inhibits the β-Lactamase from Mycobacterium tuberculosis
Hua Xu et al.
BIOCHEMISTRY (2012)
Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study
Jose A. Vazquez et al.
CURRENT MEDICAL RESEARCH AND OPINION (2012)
Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole
J. Dubreuil et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2012)
In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae
Z. Aktas et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2012)
Characterization of -lactamase and porin mutants of Enterobacteriaceae selected with ceftarolineavibactam (NXL104)
David M. Livermore et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2012)
Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor
David E. Ehmann et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Epidemiological Expansion, Structural Studies, and Clinical Challenges of New beta-Lactamases from Gram-Negative Bacteria
Karen Bush et al.
ANNUAL REVIEW OF MICROBIOLOGY, VOL 65 (2011)
Activities of NXL104 Combinations with Ceftazidime and Aztreonam against Carbapenemase-Producing Enterobacteriaceae
David M. Livermore et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Evaluation of Ceftazidime and NXL104 in Two Murine Models of Infection Due to KPC-Producing Klebsiella pneumoniae
Andrea Endimiani et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
In Vitro Activity of Ceftazidime-NXL104 against 396 Strains of β-Lactamase-Producing Anaerobes
Diane M. Citron et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
In Vitro Activity of Ceftazidime Combined with NXL104 versus Pseudomonas aeruginosa Isolates Obtained from Patients in Canadian Hospitals (CANWARD 2009 Study)
A. Walkty et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Activity of NXL104 in Combination with β-Lactams against Genetically Characterized Escherichia coli and Klebsiella pneumoniae Isolates Producing Class A Extended-Spectrum β-Lactamases and Class C β-Lactamases
P. R. S. Lagace-Wiens et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors
Ken Coleman
CURRENT OPINION IN MICROBIOLOGY (2011)
Antimicrobial susceptibility of 15,644 pathogens from Canadian hospitals: results of the CANWARD 2007-2009 study
George G. Zhanel et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2011)
Antimicrobial susceptibility of global inpatient urinary tract isolates of Escherichia coli: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program: 2009-2010
Daryl J. Hoban et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2011)
Trending Eight Years of In Vitro Activity of Ertapenem and Comparators against Escherichia coli from Intra-abdominal Infections in North America-SMART 2002-2009
S. P. Hawser et al.
JOURNAL OF CHEMOTHERAPY (2011)
Updated Functional Classification of beta-Lactamases
Karen Bush et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Mechanistic Studies of the Inactivation of TEM-1 and P99 by NXL104, a Novel Non-β-Lactam β-Lactamase Inhibitor
Therese Stachyra et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Alarming beta-lactamase-mediated resistance in multidrug-resistant Enterobacteriaceae
Karen Bush
CURRENT OPINION IN MICROBIOLOGY (2010)
Infections with Extended-Spectrum beta-Lactamase-Producing Enterobacteriaceae Changing Epidemiology and Drug Treatment Choices
Johann D. D. Pitout
DRUGS (2010)
In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters
Shazad Mushtaq et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)
In Vitro Activity of NXL104 in Combination with β-Lactams against Klebsiella pneumoniae Isolates Producing KPC Carbapenemases
Andrea Endimiani et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
MYSTIC Europe 2007: activity of meropenem and other broad-spectrum agents against nosocomial isolates
Philip J. Turner
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2009)
Ceftaroline A Novel Broad-Spectrum Cephalosporin with Activity against Meticillin-Resistant Staphylococcus aureus
George G. Zhanel et al.
DRUGS (2009)
In vitro activity of the β-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases
Therese Stachyra et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2009)
Has the era of untreatable infections arrived?
David M. Livermore
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2009)
NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum β-lactamases and carbapenemases
David M. Livermore et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
Zinc and antibiotic resistance: metallo-beta-lactamases and their synthetic analogues
A. Tamilselvi et al.
JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY (2008)
Peptidoglycan structure and architecture
Waldemar Vollmer et al.
FEMS MICROBIOLOGY REVIEWS (2008)
The penicillin-binding proteins: structure and role in peptidoglycan biosynthesis
Eric Sauvage et al.
FEMS MICROBIOLOGY REVIEWS (2008)
Piperacillin-tazobactam:: a β-lactam/β-lactamase inhibitor combination
Alfred Gin et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2007)
The beta-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter
David M. Livermore et al.
TRENDS IN MICROBIOLOGY (2006)
Resistance to β-lactam antibiotics
K Poole
CELLULAR AND MOLECULAR LIFE SCIENCES (2004)
In vitro activity of AVE1330A, an innovative broad-spectrum non-β-lactam β-lactamase inhibitor
A Bonnefoy et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2004)
Role of penicillin-binding proteins in bacterial cell morphogenesis
DL Popham et al.
CURRENT OPINION IN MICROBIOLOGY (2003)
Molecular analysis of beta-lactamase structure and function
FK Majiduddin et al.
INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY (2002)
Share Paper
